Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas.

Naka KK, Papathanassiou K, Bechlioulis A, Pappas K, Kazakos N, Kanioglou C, Kostoula A, Vezyraki P, Makriyiannis D, Tsatsoulis A, Michalis LK.

Diab Vasc Dis Res. 2012 Jan;9(1):52-8. doi: 10.1177/1479164111424515. Epub 2011 Nov 2.

PMID:
22049096
2.

2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes.

Seufert J, Urquhart R.

Diabetes Res Clin Pract. 2008 Mar;79(3):453-60. Epub 2007 Dec 26.

PMID:
18160120
3.

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).

Scheen AJ, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, Charbonnel B; PROactive investigators..

Diabet Med. 2009 Oct;26(10):1033-9. doi: 10.1111/j.1464-5491.2009.02816.x.

PMID:
19900236
4.

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group..

Diabetes Care. 2004 Jan;27(1):141-7.

PMID:
14693980
5.
6.

Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.

Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT.

Drugs Aging. 2004;21(4):259-71.

PMID:
15012171
7.

Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin.

Naka KK, Papathanassiou K, Bechlioulis A, Pappas K, Kazakos N, Kanioglou C, Papafaklis MI, Kostoula A, Vezyraki P, Makriyiannis D, Tsatsoulis A, Michalis LK.

Diab Vasc Dis Res. 2011 Jul;8(3):195-201. doi: 10.1177/1479164111408628. Epub 2011 May 16.

PMID:
21576196
8.
9.

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Metabolism. 2010 Jun;59(6):887-95. doi: 10.1016/j.metabol.2009.10.007. Epub 2009 Dec 16.

PMID:
20015525
10.

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.

Martens FM, Visseren FL, de Koning EJ, Rabelink TJ.

J Cardiovasc Pharmacol. 2005 Dec;46(6):773-8.

PMID:
16306801
11.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
12.

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

Scheen AJ, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, Charbonnel B; PROactive investigators..

Diabet Med. 2009 Dec;26(12):1242-9. doi: 10.1111/j.1464-5491.2009.02857.x.

PMID:
20002476
13.

[Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].

Rodríguez A, Reviriego J, Polavieja P, Mesa J.

Med Clin (Barc). 2008 Nov 29;131(19):721-30. Spanish.

PMID:
19091199
14.

Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes.

Papathanassiou K, Naka KK, Kazakos N, Kanioglou C, Makriyiannis D, Pappas K, Katsouras CS, Liveris K, Kolettis T, Tsatsoulis A, Michalis LK.

Atherosclerosis. 2009 Jul;205(1):221-6. doi: 10.1016/j.atherosclerosis.2008.11.027. Epub 2008 Dec 6.

PMID:
19135671
15.

Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus.

Roden M, Laakso M, Johns D, Widel M, Urquhart R, Richardson C, Mariz S, Tan MH.

Diabet Med. 2005 Aug;22(8):1101-6.

PMID:
16026380
16.

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.

BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369.

17.

Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.

Roden M, Mariz S, Brazzale AR, Pacini G.

J Intern Med. 2009 Apr;265(4):476-87. doi: 10.1111/j.1365-2796.2008.02040.x.

18.

Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.

Comaschi M, Demicheli A, Di Pietro C, Bellatreccia A, Mariz S; COM06 Study Investigators..

Diabetes Technol Ther. 2007 Aug;9(4):387-98.

PMID:
17705695
19.

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.

Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M.

Diabetologia. 2005 Jun;48(6):1093-104. Epub 2005 May 12.

PMID:
15889234
20.

Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).

Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.

Diabetes Obes Metab. 2009 Jan;11(1):27-32. Epub 2007 Oct 17.

PMID:
17941873

Supplemental Content

Support Center